Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients
Purpose: To evaluate the pharmacokinetics of weekly docetaxel in a cohort of older patients with metastatic cancer and to explore the relationship of pharmacokinetic variables, Erythromycin Breath Test results, age, geriatric assessment variables, and toxicity to therapy. Experimental Design: Twenty...
Saved in:
Published in | Clinical cancer research Vol. 12; no. 20; pp. 6100 - 6105 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.10.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: To evaluate the pharmacokinetics of weekly docetaxel in a cohort of older patients with metastatic cancer and to explore
the relationship of pharmacokinetic variables, Erythromycin Breath Test results, age, geriatric assessment variables, and
toxicity to therapy.
Experimental Design: Twenty patients ages ≥65 years with metastatic breast, prostate, or lung cancer entered an Institutional Review Board–approved
protocol to evaluate the pharmacokinetics of weekly docetaxel administered at 35 mg/m 2 i.v. for 3 weeks followed by a 1-week break. The Erythromycin Breath Test and geriatric assessment were done before the first
dose. Blood samples were collected for pharmacokinetic analysis with the first dose of docetaxel.
Results: Of the 20 patients who entered the study, 19 were evaluable. There were no age-related differences in the pharmacokinetics
of weekly docetaxel. Fifty-eight percent (11 of 19) experienced grade ≥3 toxicity: 16% (3 of 19) grade ≥3 hematologic toxicity,
and 53% (10 of 19) grade ≥3 nonhematologic toxicity. There was an association between the Erythromycin Breath Test results
and docetaxel pharmacokinetic variables; however, there was no association between Erythromycin Breath Test results or docetaxel
pharmacokinetics with frequency of grade ≥3 toxicity.
Conclusions: Despite no statistically significant age-related differences in weekly docetaxel pharmacokinetics, over half of these older
patients experienced a grade ≥3 toxicity at the 35 mg/m 2 starting dose. We advocate a starting dose of 26 mg/m 2 on this weekly schedule and dose escalating if no toxicity. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-06-0200 |